Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · IEX Real-Time Price · USD
2.060
-0.290 (-12.34%)
At close: Jul 2, 2024, 4:00 PM
2.080
+0.020 (0.97%)
After-hours: Jul 2, 2024, 7:15 PM EDT
Werewolf Therapeutics Revenue
Werewolf Therapeutics had revenue of $16.22M in the twelve months ending March 31, 2024, down -22.26% year-over-year. Revenue in the quarter ending March 31, 2024 was $742.00K, a -83.38% decrease year-over-year. In the year 2023, Werewolf Therapeutics had annual revenue of $19.94M with 21.60% growth.
Revenue (ttm)
$16.22M
Revenue Growth
-22.26%
P/S Ratio
5.52
Revenue / Employee
$352,630
Employees
46
Market Cap
89.52M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 19.94M | 3.54M | 21.60% |
Dec 31, 2022 | 16.40M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHOWL News
- 7 days ago - Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - GlobeNewsWire
- 4 weeks ago - Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors - GlobeNewsWire
- 4 weeks ago - Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting - GlobeNewsWire